AI-generated summary
The authors compared topical methimazole 5% alone with methimazole combined with Q-switched Nd:YAG laser in 27 women with refractory melasma, using split-face treatment over 12 weeks. Physician satisfaction was higher with the combination at weeks 4, 8 and 12, and physician global assessment improved more over time, while other measures did not differ significantly. The authors describe the combination as potentially effective, though the small sample size limits certainty.
- Participants
- 27
- Who or what was studied
- Women with refractory melasma
- Wavelengths
- 1064 nm
- Limits stated in the abstract
- Small sample of 27 women, with no stated control group beyond the untreated-laser half-face comparison and several outcomes not significantly different.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
Introduction
Melasma is an acquired pigmentary disorder which currently has no definitive treatment. Although topical drugs containing hydroquinone are the basis of treatments, they are usually associated with recurrence. We aimed to evaluate the effectiveness and safety of monotherapy with topical methimazole 5% versus combination of Q-Switched Nd: YAG Laser and topical methimazole 5% in patients with refractory melasma.
Methods
A total of 27 women with refractory melasma were included. We applied topical methimazole 5% (once a day) with three passes of QSNd: YAG laser (Wavelength: 1064 nm, pulse energy: 750 mJ, fluence: 1.50 J/cm2 , spot size: 4 × 4 mm, hand piece: fractional, JEISYS company) for six sessions on the right half of the face, and topical methimazole 5% (once a day) on the left half of the face, for each patient. The treatment course was 12 weeks. Evaluation of effectiveness was done with the Physician Global Assessment (PGA), Patient Global Assessment (PtGA), Physician satisfaction (PS), Patients satisfaction (PtS), and mMASI score.
Results
PGA, PtGA, and PtS were not significantly different between the two groups at any time (p > 0.05). PS in the laser plus methimazole group was significantly better than methimazole group at 4th, 8th, and 12th weeks (p < 0.05). The rate of PGA improvement in the combination group was significantly better than the monotherapy over time (p < 0.001). The changes of mMASI score between the two groups did not significantly differ at any time (p > 0.05). There was no significant difference in the adverse events between the two groups.
Conclusion
Combination therapy with topical methimazole 5% and QSNY laser can be considered as an effective way to treat refractory melasma.
Abstract reproduced under the CC BY license. Source: PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 1064 nm
- Energy density (fluence)
- 1.50 J/cm2
How to read a single study: what to check before relying on this kind of research.
Terms in this paper: Laser, Wavelength, Fluence. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.